2. Search Result
Search Result
Results for "

Antiplatelet Agent

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

5

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112575
    Tiazotic acid

    		Others Infection Cardiovascular Disease Inflammation/Immunology
    Tiazotic acid is a metabolic agent that has immunomodulatory, anti-inflammatory, antioxidant, anti-ischemic, cardio- and endothelioprotective, antiplatelet, hepatoprotective activities. Tiazotic acid increases the levels of eNOS. Tiazotic acid also reduces the level of D-dimer in the blood, which reduces the risks of heart attacks and strokes in post-COVID syndrome .
    Tiazotic acid
  • HY-118025
    (±)-2-Oxo clopidogrel

    (±)-SR-121683

    		 Others Others
    (±)-2-Oxo clopidogrel is a metabolite of the antiplatelet agent Clopidogrel (HY-15283) .
    (±)-2-Oxo clopidogrel
  • HY-N3729
    (-)-Denudatin B

    Denudatin B

    		 Calcium Channel Cardiovascular Disease
    (-)-Denudatin B is an antiplatelet agent. (-)-Denudatin B relaxed vascular smooth muscle by inhibiting the Ca2+ influx through voltage-gated and receptor-operated Ca2+ channels . And (-)-Denudatin B has nonspecific antiplatelet action
    (-)-Denudatin B
  • HY-146498
    Antiplatelet agent 1

    		P2Y Receptor Cardiovascular Disease Cancer
    Antiplatelet agent 1 (compound 7q) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 1 can be used for researching platelet aggregation .
    Antiplatelet agent 1
  • HY-146499
    Antiplatelet agent 2

    		P2Y Receptor Cardiovascular Disease Cancer
    Antiplatelet agent 2 (compound 7p) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 2 can be used for researching platelet aggregation .
    Antiplatelet agent 2
  • HY-111755
    Oral antiplatelet agent 1

    		P2Y Receptor Cardiovascular Disease
    Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
    Oral antiplatelet agent 1
  • HY-N1861
    3-O-Methylquercetin tetraacetate

    Quercetin 3-O-methyl ether peracetate

    		 P2Y Receptor Cardiovascular Disease Cancer
    3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .
    3-O-Methylquercetin tetraacetate
  • HY-N1723
    2-Deacetoxytaxinine B

    		Others Cardiovascular Disease
    2-Deacetoxytaxinine B is a potent antiplatelet agent .
    2-Deacetoxytaxinine B
  • HY-N3048
    Piperlotine D

    		Others Cardiovascular Disease
    Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC50 of 43.4 μg/mL .
    Piperlotine D
  • HY-U00039
    Desethyl KBT-3022

    		Thrombin Cardiovascular Disease
    Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022.
    Desethyl KBT-3022
  • HY-B0428
    Ozagrel
    1 Publications Verification

    OKY-046

    		 Prostaglandin Receptor Cardiovascular Disease
    Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
    Ozagrel
  • HY-B0312
    Dipyridamole
    4 Publications Verification

    		 Phosphodiesterase (PDE) Apoptosis Cardiovascular Disease Cancer
    Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .
    Dipyridamole
  • HY-B0428A
    Ozagrel sodium
    1 Publications Verification

    OKY-046 sodium

    		 Prostaglandin Receptor Cardiovascular Disease
    Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
    Ozagrel sodium
  • HY-B0428B
    Ozagrel hydrochloride
    1 Publications Verification

    OKY-046 hydrochloride

    		 Prostaglandin Receptor Cardiovascular Disease
    Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
    Ozagrel hydrochloride
  • HY-119410
    Linotroban

    HN11500

    		 Prostaglandin Receptor Cardiovascular Disease
    Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent .
    Linotroban
  • HY-162558
    NCGC00351170

    		Factor Xa Cardiovascular Disease
    NCGC00351170 is an antiplatelet agent that disrupts the calcium and integrin-binding protein 1 (CIB1)-αIIbβ3 interaction. NCGC00351170 inhibits thrombin-induced human platelet aggregation .
    NCGC00351170
  • HY-118025R
    (±)-2-Oxo clopidogrel (Standard)

    		Others Others
    (±)-2-Oxo clopidogrel (Standard) is the analytical standard of (±)-2-Oxo clopidogrel. This product is intended for research and analytical applications. (±)-2-Oxo clopidogrel is a metabolite of the antiplatelet agent Clopidogrel (HY-15283) .
    (±)-2-Oxo clopidogrel (Standard)
  • HY-A0221
    Ridogrel

    R 68070

    		 Prostaglandin Receptor Inflammation/Immunology
    Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .
    Ridogrel
  • HY-118284
    Vicagrel
    1 Publications Verification

    		 P2Y Receptor Cardiovascular Disease
    Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
    Vicagrel
  • HY-106080A
    Furegrelate sodium

    U-63557A

    		 Prostaglandin Receptor Cardiovascular Disease
    Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
    Furegrelate sodium
  • HY-107867
    (±)-Clopidogrel bisulfate

    		Others Cardiovascular Disease
    Clopidogrel sulfate is an antiplatelet agent. Specifically, Clopidogrel sulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel sulfate can be used for research of heart disease and stroke .
    (±)-Clopidogrel bisulfate
  • HY-18200
    Atopaxar

    E5555; ER-172594-00

    		 Protease Activated Receptor (PAR) JAK Apoptosis Cardiovascular Disease Cancer
    Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease .
    Atopaxar
  • HY-106080
    Furegrelate

    U-63557A free acid

    		 Prostaglandin Receptor Cardiovascular Disease
    Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent .
    Furegrelate
  • HY-125615
    DMP 728 methanesulfonate

    		Glycoprotein VI Cardiovascular Disease Others
    DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .
    DMP 728 methanesulfonate
  • HY-141749AS
    Clopidogrel carboxylic acid-d4

    CLPM-d4; SR 26334-d4

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Clopidogrel carboxylic acid-d4 is a deuterated derivative of Clopidogrel carboxylic acid, which is an inactive metabolite of the antiplatelet agent Clopidogrel (HY-15283) in plasma. Clopidogrel carboxylic acid-d4 can be used to further explore the metabolic characteristics of Clopidogrel .
    Clopidogrel carboxylic acid-d4
  • HY-B0312R
    Dipyridamole (Standard)

    		Phosphodiesterase (PDE) Apoptosis Cardiovascular Disease Cancer
    Dipyridamole (Standard) is the analytical standard of Dipyridamole. This product is intended for research and analytical applications. Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .
    Dipyridamole (Standard)
  • HY-B0428BR
    Ozagrel hydrochloride (Standard)

    		Prostaglandin Receptor Cardiovascular Disease
    Ozagrel (hydrochloride) (Standard) is the analytical standard of Ozagrel (hydrochloride). This product is intended for research and analytical applications. Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
    Ozagrel hydrochloride (Standard)
  • HY-18200B
    Atopaxar hydrobromide

    E5555 hydrobromide; ER 172594-06

    		 Protease Activated Receptor (PAR) JAK Apoptosis Cardiovascular Disease Cancer
    Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease .
    Atopaxar hydrobromide
  • HY-167743
    Platelet aggregation-IN-2

    		Others Cardiovascular Disease
    Platelet aggregation-IN-2 is an anti-platelet aggregation agent with significant anticoagulant activity. Platelet aggregation-IN-2 can inhibit platelet aggregation reaction and reduce the risk of thrombosis. The application of Platelet aggregation-IN-2 can potentially be used for the prevention and suppression of cardiovascular diseases .
    Platelet aggregation-IN-2
  • HY-N6005
    Methyl caffeate

    		Bacterial Infection Cancer
    Methyl caffeate, an antimicrobial agent, shows moderate antimicrobial and prominent antimycobacterial activities. Methyl caffeate also exhibits α-glucosidase inhibition activity, oxidative stress inhibiting activity, anti-platelet activity, antiproliferative activity in cervix adenocarcinoma and anticancer activity in lung and leukmia cell lines .
    Methyl caffeate
  • HY-10119
    Vorapaxar
    5+ Cited Publications

    SCH 530348

    		 Protease Activated Receptor (PAR) Cardiovascular Disease
    Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar
  • HY-10119A
    Vorapaxar sulfate
    5+ Cited Publications

    SCH 530348 sulfate

    		 Protease Activated Receptor (PAR) Cardiovascular Disease
    Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar sulfate
  • HY-123669A
    trans-R-138727

    		P2Y Receptor Cardiovascular Disease
    Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptor P2Y12, and inhibits ADP-induced platelet activation and aggregation .
    trans-R-138727
  • HY-17459
    Clopidogrel hydrogen sulfate
    Maximum Cited Publications
    22 Publications Verification

    (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate

    		 Cytochrome P450 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel hydrogen sulfate
  • HY-10119S
    Vorapaxar-d5

    SCH 530348-d5

    		 Protease Activated Receptor (PAR) Isotope-Labeled Compounds Cardiovascular Disease
    Vorapaxar-d5 is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar-d5
  • HY-10119R
    Vorapaxar (Standard)

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    Vorapaxar (Standard) is the analytical standard of Vorapaxar. This product is intended for research and analytical applications. Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar (Standard)
  • HY-115911
    GPVI antagonist 2

    		Glycoprotein VI Cardiovascular Disease
    GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .
    GPVI antagonist 2
  • HY-115912
    GPVI antagonist 3

    		Glycoprotein VI Cardiovascular Disease
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .
    GPVI antagonist 3
  • HY-10119AR
    Vorapaxar (sulfate) (Standard)

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    Vorapaxar (sulfate) (Standard) is the analytical standard of Vorapaxar (sulfate). This product is intended for research and analytical applications. Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar (sulfate) (Standard)
  • HY-17459S
    Clopidogrel-d3 hydrogen sulfate

    (S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate

    		 P2Y Receptor Cytochrome P450 Cardiovascular Disease
    Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
    Clopidogrel-d3 hydrogen sulfate
  • HY-17459R
    Clopidogrel (hydrogen sulfate) (Standard)

    (S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)

    		 Cytochrome P450 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel (hydrogen sulfate) (Standard)
  • HY-78263
    MNS

    NSC 170724; 5-(2-Nitrovinyl)benzodioxole

    		 Src Syk Cancer
    MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively .
    MNS
  • HY-160615
    TP receptor antagonist-1

    		Prostaglandin Receptor Cardiovascular Disease Inflammation/Immunology
    TP receptor antagonist-1 (compound 7m) is a thromboxane A2 receptor (TP receptor) antagonist, with IC50 values of 9.46 μM for TPa and 8.49 μM for TPb, respectively. TP receptor antagonist-1 can be used for the research of cardiovascular disease .
    TP receptor antagonist-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: